Daniel O'Day, Gilead CEO (Andrew Harnik/AP Images)
Gilead to snap up liver disease biotech CymaBay for $4.3B
Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
